Superworth

Intellia Therapeutics EPS NTLA

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$3.36
Latest quarter, Q2 FY26
−$0.80
Fiscal year 2025
−$3.83

Intellia Therapeutics' earnings per share was −$3.36 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.80.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.83n/a
FY2024−$5.25n/a
FY2023−$5.41n/a
FY2022−$6.18n/a
FY2021−$3.76n/a
FY2020−$2.40n/a
FY2019−$2.11n/a
FY2018−$1.99n/a
FY2017−$1.86n/a
FY2016−$10.78n/a
FY2015−$23.06n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.80n/a−$3.36
Q1 FY26−$0.81n/a−$3.54
Q4 FY25−$0.83n/a−$3.83
Q3 FY25−$0.92n/a−$4.27
Q2 FY25−$0.98n/a−$4.69
Q1 FY25−$1.10n/a−$5.23
Q4 FY24−$1.27n/a−$5.25
Q3 FY24−$1.34n/a−$5.44
Q2 FY24−$1.52n/a−$5.48
Q1 FY24−$1.12n/a−$5.36
Q4 FY23−$1.46n/a−$5.41
Q3 FY23−$1.38n/a−$5.35

Against its peers

Companies in Medical - Diagnostics & Research nearest Intellia Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
NTLAIntellia Therapeutics−$3.36
CDNACareDx$2.07+116% a year
VCYTVeracyte$1.40+324% a year
BLLNBillionToOne$0.65
NRCNRC Health$0.25−67% a year
LNTHLantheus$4.13+10% a year
CAICaris Life Sciences$0.37
BIOBio-Rad Laboratories$8.25−30% a year
Peer median$1.40

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Intellia Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.